Candel Therapeutics (CADL) Total Current Liabilities (2020 - 2025)
Candel Therapeutics (CADL) reported Total Current Liabilities of $9.0 million for Q4 2025, down 76.03% on a YoY basis from $37.5 million in Q4 2024, and down 17.68% sequentially from $10.9 million in Q3 2025.
Candel Therapeutics (CADL) Total Current Liabilities (2020 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 6 years of Total Current Liabilities data on file, last reported at $9.0 million in Q4 2025.
- For the quarter ending Q4 2025, Total Current Liabilities fell 76.03% year-over-year to $9.0 million; the trailing twelve-month figure through Dec 2025 stood at $9.0 million (down 76.03% YoY), and the FY2025 full-year result was $9.0 million, down 76.03% from the prior year.
- Total Current Liabilities declined to $9.0 million in Q4 2025, from $10.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $37.5 million in Q4 2024 to a low of $4.4 million in Q3 2021.
- A 5-year average of $11.1 million and a median of $9.0 million in 2025 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities soared 164.59% in 2024 and plunged 76.03% in 2025, its largest moves.
- Tracing CADL's Total Current Liabilities over 5 years: stood at $5.4 million in 2021, then climbed by 4.72% to $5.6 million in 2022, then soared by 152.61% to $14.2 million in 2023, then jumped by 164.59% to $37.5 million in 2024, then sank by 76.03% to $9.0 million in 2025.
- Business Quant data shows CADL's Total Current Liabilities at $9.0 million in Q4 2025, $10.9 million in Q3 2025, and $14.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Candel Therapeutics | 542.51 Mn | 542.51 Mn | - | 9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | 10.93 Mn |
| Jun 30, 2025 | 14.72 Mn |
| Mar 31, 2025 | 20.07 Mn |
| Dec 31, 2024 | 37.53 Mn |
| Sep 30, 2024 | 15.27 Mn |
| Jun 30, 2024 | 14.00 Mn |
| Mar 31, 2024 | 13.54 Mn |
| Dec 31, 2023 | 14.18 Mn |
| Sep 30, 2023 | 10.33 Mn |
| Jun 30, 2023 | 8.16 Mn |
| Mar 31, 2023 | 5.24 Mn |
| Dec 31, 2022 | 5.62 Mn |
| Sep 30, 2022 | 5.90 Mn |
| Jun 30, 2022 | 5.88 Mn |
| Mar 31, 2022 | 5.47 Mn |
| Dec 31, 2021 | 5.36 Mn |
| Sep 30, 2021 | 4.40 Mn |
| Jun 30, 2021 | 4.49 Mn |
| Dec 31, 2020 | 4.71 Mn |